NASDAQ: VTGNVistagen Therapeutics Inc Stock
$0.52-0.01 (-1.89%)
Updated Feb 18, 2026
VTGN Price
$0.52
Fair Value Price
N/A
Market Cap
$20.44M
52 Week Low
$0.43
52 Week High
$5.14
P/E
-0.27x
P/B
0.4x
P/S
35.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$790.00k
Earnings
-$67.05M
Gross Margin
100%
Operating Margin
-8,486.84%
Profit Margin
-8,486.8%
Debt to Equity
0.28
Operating Cash Flow
-$60M
Beta
1.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VTGN Overview
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VTGN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VTGN
Ranked#243 of 476
Ranked#243 of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $5.22 | A | |
| $7.26 | A | |
| $168.72 | A |
Be the first to know about important VTGN news, forecast changes, insider trades & much more!
VTGN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VTGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VTGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VTGN is good value based on its book value relative to its share price (0.4x), compared to the US Biotechnology industry average (5.18x)
P/B vs Industry Valuation
VTGN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VTGN due diligence checks available for Premium users.
Valuation
VTGN fair value
Fair Value of VTGN stock based on Discounted Cash Flow (DCF)
Price
$0.52
Fair Value
$2.13
Undervalued by
75.56%
VTGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VTGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.27x
Industry
206.89x
Market
44.36x
VTGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.4x
Industry
5.18x
VTGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VTGN's financial health
Profit margin
Revenue
$303.0k
Net Income
-$18.9M
Profit Margin
-6,237.3%
VTGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VTGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$65.1M
Liabilities
$14.1M
Debt to equity
0.28
VTGN's short-term assets ($63.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VTGN's short-term assets ($63.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VTGN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VTGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.6M
Investing
$104.0k
Financing
$2.1M
VTGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VTGN vs Biotech Stocks
Vistagen Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.